异动解读｜科伦博泰生物盘中上涨3.12%，ASCO年会重磅数据持续催化管线价值重估

行情直击05-26

5月26日，科伦博泰生物盘中上涨3.12%，报483.8港元，成交额1.87亿港元。消息面上，公司近期研发利好密集释放，持续催化股价表现。

公司此前公告将在ASCO年会上公布多项临床研究成果，核心产品TROP2 ADC芦康沙妥珠单抗及RET抑制剂富马酸仑博替尼两项注册研究入选转移性非小细胞肺癌口头报告专场。数据显示，sac-TMT联合帕博利珠单抗一线治疗PD-L1阳性晚期非小细胞肺癌III期临床已达主要终点，客观缓解率提升至70.2%，系全球首个在一线NSCLC中击败Keytruda单药的ADC-免疫联合方案。此外，中邮证券首次覆盖公司并给予"买入"评级，认为管线全球价值兑现在即。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1108779178?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-26 10:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108779178","market":"hk","top_or_hot":-1,"title":"异动解读｜科伦博泰生物盘中上涨3.12%，ASCO年会重磅数据持续催化管线价值重估","media":"行情直击","content":"<p><p>5月26日，科伦博泰生物盘中上涨3.12%，报483.8港元，成交额1.87亿港元。消息面上，公司近期研发利好密集释放，持续催化股价表现。</p><p>公司此前公告将在ASCO年会上公布多项临床研究成果，核心产品TROP2 ADC芦康沙妥珠单抗及RET抑制剂富马酸仑博替尼两项注册研究入选转移性非小细胞肺癌口头报告专场。数据显示，sac-TMT联合帕博利珠单抗一线治疗PD-L1阳性晚期非小细胞肺癌III期临床已达主要终点，客观缓解率提升至70.2%，系全球首个在一线NSCLC中击败Keytruda单药的ADC-免疫联合方案。此外，中邮证券首次覆盖公司并给予\"买入\"评级，认为管线全球价值兑现在即。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜科伦博泰生物盘中上涨3.12%，ASCO年会重磅数据持续催化管线价值重估</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜科伦博泰生物盘中上涨3.12%，ASCO年会重磅数据持续催化管线价值重估\n</h2>\n\n<h4 class=\"meta\">\n\n2026-05-26 10:19 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月26日，科伦博泰生物盘中上涨3.12%，报483.8港元，成交额1.87亿港元。消息面上，公司近期研发利好密集释放，持续催化股价表现。公司此前公告将在ASCO年会上公布多项临床研究成果，核心产品TROP2 ADC芦康沙妥珠单抗及RET抑制剂富马酸仑博替尼两项注册研究入选转移性非小细胞肺癌口头报告专场。数据显示，sac-TMT联合帕博利珠单抗一线治疗PD-L1阳性晚期非小细胞肺癌III期临床已达...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1108779178","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108779178","pubTimestamp":1779761970,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"5月26日，科伦博泰生物盘中上涨3.12%，报483.8港元，成交额1.87亿港元。消息面上，公司近期研发利好密集释放，持续催化股价表现。公司此前公告将在ASCO年会上公布多项临床研究成果，核心产品TROP2 ADC芦康沙妥珠单抗及RET抑制剂富马酸仑博替尼两项注册研究入选转移性非小细胞肺癌口头报告专场。此外，中邮证券首次覆盖公司并给予\"买入\"评级，认为管线全球价值兑现在即。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"Interpretation of the change | Kelun Botai Biotech rose 3.12% in the intraday session, and the heavy data of ASCO annual meeting continued to catalyze the revaluation of pipeline value","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"5月26日，科伦博泰生物盘中上涨3.12%，报483.8港元，成交额1.87亿港元。消息面上，公司近期研发利好密集释放，持续催化股价表现。公司此前公告将在ASCO年会上公布多项临床研究成果，核心产品TROP2 ADC芦康沙妥珠单抗及RET抑制剂富马酸仑博替尼两项注册研究入选转移性非小细胞肺癌口头报告专场。数据显示，sac-TMT联合帕博利珠单抗一线治疗PD-L1阳性晚期非小细胞肺癌III期临床已达主要终点，客观缓解率提升至70.2%，系全球首个在一线NSCLC中击败Keytruda单药的ADC-免疫联合方案。此外，中邮证券首次覆盖公司并给予\"买入\"评级，认为管线全球价值兑现在即。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108779178","isCrawlerRequest":true}